iwNHL 2016 Highlights

To view all videos from the event please click here

Day 1 highlights

John Gribben, MD, DSc, FRCPath, FMed Sci of Barts Cancer Institute, London, UK discusses the highlights from the first day of the 2016 International Workshop on Non-Hodgkin Lymphoma (iwNHL) meeting held in San Diego, CA with Laurence de Leval, MD, PhD of University Hospital of Lausanne, Lausanne, Switzerland, Wyndham Wilson, MD, PhD of the National Cancer Institute, Bethesda, MD and Catherine Bollard, MBChB, MD, FRACP, FRCPA of the Children's National Health System, Washington, DC.

Topics discussed include T-cell lymphoma, treating pediatric patients, diffuse large B-cell lymphoma (DLBCL), and novel therapies (including CAR T-cell therapy).

Day 2 highlights

John Gribben, MD, DSc, FRCPath, FMed Sci of Barts Cancer Institute, London, UK discusses the highlights from the second day of the 2016 International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2016 meeting held in San Diego, CA with Anas Younes, MD of Memorial Sloan Kettering Cancer Center, New York, NY, Simon Rule, MD of Plymouth University, Plymouth, UK and Michael Pfreundschuh, MD of Saarland University, Saarbrücken, Germany.

Topics include the new guidelines for response, diffuse large B-cell lymphoma (DLBCL) subtypes and treatment, mantle cell lymphoma (MCL), and novel therapies (in particular IMiDs and their role in lymphomas).

Panel discussion on large cell lymphomas: subtypes, patient selection and mutations

Andrew Zelenetz, MD, PhD of Memorial Sloan Kettering Cancer Center, New York, NY talks about large cell lymphoma with Michael Pfreundschuh, MD of Saarland University, Saarbrücken, Germany, David Scott, MBChB, PhD of British Columbia Cancer Agency, Vancouver, BC and Laura Pasqualucci, MD of Columbia University Medical Center, New York, NY.

Panel discussion on T-cell lymphoma: current status of therapy and progress

John Gribben, MD, DSc, FRCPath, FMed Sci of Barts Cancer Institute, London, UK introduces the panel discussion on T-cell lymphoma at the 2016 International Workshop on Non-Hodgkin Lymphoma (iwNHL) meeting held in San Diego, CA. Prof. Gribben is joined by Laurence de Leval, MD, PhD of University Medical Center (CHUV), Lausanne, Switzerland, Francine Foss, MD of Yale School of Medicine, New Haven, CT and Elaine Jaffe, MD of the National Cancer Institute, Bethesda, MD.

Topics include the classification of T-cell lymphomas, targeted therapies, trials of brentuximab vedotin, and biomarkers for prognosis.

iwNHL 2016 highlights: CAR T-cell therapy, DLBCL and new technologies

Andrew Davies, MRCP, PhD of University Hospital of Southampton, Southampton, UK discusses his highlights from the 2016 International Workshop on Non-Hodgkin Lymphoma (iwNHL) meeting held in San Diego, CA.

Discussion of the two biologies of DLBCL - the GCB and ABC subtype and potential targeted therapies

Clemens Schmitt, MD of the Max Delbruck Center for Molecular Medicine, Berlin, Germany discusses the ongoing debate about the two biologies of diffuse large B-cell lymphoma (DLBCL), i.e. cell of origin discussion about germinal center B-cell (GCB) vs activated B-cell (ABC) subtype.

Results of trial on the use of interim PET scan to identify DLBCL

Laurie Sehn, MD of British Columbia Cancer Agency, Vancouver, Canada discusses the use of PET scan to identify diffuse large B-cell lymphoma (DLBCL) patients who will do poorly on frontline therapy.

Current projects at City of Hope: CAR T-cells, vaccines and a novel nuceloside analogue

Steven Rosen, MD of City of Hope, Duarte, CA discusses projects currently underway at the City of Hope. This includes CAR T-cells, vaccine trials for solid tumors, blood cancers and infections, stem cells, a novel nucleoside analogue that is RNA directed rather than DNA directed, and further, the re-purposing of a drug for arthritis (flutamide) for multiple myeloma (MM).

The potential clinical implications of targeted therapies for DLBCL and why the situation is complex

Clemens Schmitt, MD of the Max Delbruck Center for Molecular Medicine, Berlin, Germany discusses the clinical implications of targeted therapies for diffuse large B-cell lymphoma (DLBCL).

The standard of care for DLBCL and double-hit lymphoma

Laurie Sehn, MD of British Columbia Cancer Agency, Vancouver, Canada discusses the standard of care for patients with diffuse large B-cell lymphoma (DLBCL).

Upcoming trials for DLBCL: R-CHOP with acalabrutinib and obinutuzumab with checkpoint inhibitor

Andrew Davies, MRCP, PhD of University Hospital of Southampton, Southampton, UK talks about upcoming trials in diffuse large B-cell lymphoma (DLBCL).

The work and mission of City of Hope

Steven Rosen, MD of City of Hope, Duarte, CA discusses the work done at the City of Hope. Prof. Rosen explains that it is a free-standing cancer center with four areas of focus, i.e. cancer, diabetes and metabolism, HIV research and stem cell biology and regenerative medicine.

Targeted molecular signatures of DLBCL and upcoming CheckMate 647 trial for PCNSL and PTL

Bjoern Chapuy, MD, PhD of Dana-Farber Cancer Institute, Boston, MA gives an overview of his talk on targeted molecular signatures of diffuse large B-cell lymphoma (DLBCL).

16th International Workshop on Non-Hodgkin Lymphoma

Nice, France

Sep

21–23

2018 Meeting

Location

Hotel Le Meridien
1 Prom. des Anglais, 06046 Nice, France

© 2014 - 2019 World Health Communications Ltd